It looks like you are using an older version of Internet Explorer which is not supported. We advise that you update your browser to the latest version of Microsoft Edge, or consider using other browsers such as Chrome, Firefox or Safari.


Biosimilars can help reduce the high cost of oncology medicines spending1

Oncology innovation is booming, but costly for the healthcare system1,2

US oncology medicines spending continues to rise2


*Costs through 2026 are based on data reported by the IQVIA Oncology Link from April 2022. Costs beyond 2022 are projected growth based on a CAGR of 10.6% in the next 5 years.2

Biosimilars create early and expanded 
patient access to life-changing biologics 
 increasing healthcare savings and 
fueling innovation4

CAGR=compound annual growth rate; G-CSF=granulocyte colony-stimulating factor.

References: 1. IQVIA Institute for Human Data Science. Global oncology trends 2018: innovation, expansion and disruption. Accessed May 24, 2023. 2. IQVIA Institute for Human Data Science. Global oncology trends 2022: outlook to 2026. Accessed May 24, 2022. 3. IQVIA Institute for Human Data Science. Global oncology trends 2019: therapeutics, clinical development and health system implications. Accessed June 12, 2023. 4. Socal M, Ballreich J, Chyr L, Anderson G. Biosimilar medications—savings opportunities for large employers. A report for ERIC—the ERISA Industry Committee. Department of Health Policy and Management. John Hopkins Bloomberg School of Public Health. March 2020.